文献速递妇科

新辅助化疗及间隔减瘤术后腹腔化疗对晚期卵巢癌结局的影响

Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-01-11

该回顾性研究纳入2004年1月至2017年4月间接受新辅助化疗后行理想间隔肿瘤减灭术的134例晚期卵巢癌患者,比较术后腹腔化疗与静脉化疗的结局。腹腔化疗组中位无进展生存期延长3个月(14.5 vs 11.5个月,p=0.028),总生存期无显著差异,毒性相当。

要点

  • 腹腔化疗组中位PFS较静脉组延长3个月(14.5 vs 11.5个月,p=0.028)。
  • 两组总生存期无显著差异,毒性反应相当。
  • 新辅助化疗周期数增加和减瘤术后残留病灶与PFS降低相关。

核心结论

  • 新辅助化疗及理想间隔肿瘤减灭术后行腹腔化疗较静脉化疗与PFS改善相关,且毒性无显著差异。

研究设计与样本

  • 回顾性研究,纳入2004年1月至2017年4月接受新辅助化疗后行理想间隔肿瘤减灭术的晚期卵巢癌患者134例。
  • 排除ECOG PS>1、新辅助化疗或术后化疗超过6周期、初级治疗期间接受贝伐珠单抗者。
  • 37例(28%)术后接受腹腔化疗,97例(72%)接受静脉化疗。

主要发现

  • 腹腔化疗组中位PFS为14.5个月,静脉化疗组为11.5个月,差异有统计学意义(p=0.028)。
  • 两组总生存期无显著差异。
  • 单因素分析显示新辅助化疗周期数增加(HR 1.914,95%CI 1.024-3.497)和减瘤术完成时残留病灶(HR 1.541,95%CI 1.042-2.248)与PFS降低相关。
  • 腹腔化疗与PFS增加相关(HR 0.633,95%CI 0.414-0.944),多因素分析中这些关联仍存在。
  • 两组毒性反应相当。

关键数值与推荐

  • 中位PFS:腹腔化疗组14.5个月 vs 静脉化疗组11.5个月(p=0.028)。
  • 新辅助化疗周期数增加与PFS降低相关:HR 1.914(95%CI 1.024-3.497)。
  • 减瘤术完成时残留病灶与PFS降低相关:HR 1.541(95%CI 1.042-2.248)。
  • 腹腔化疗与PFS增加相关:HR 0.633(95%CI 0.414-0.944)。

临床怎么用

  • 对接受新辅助化疗及理想间隔肿瘤减灭术的晚期卵巢癌患者,术后可考虑腹腔化疗以改善无进展生存。
  • 决策时需结合患者年龄、新辅助化疗周期数及减瘤术后残留病灶情况综合评估。

局限性

  • 为单中心回顾性研究,样本量134例,存在选择偏倚可能。
  • 腹腔化疗组与静脉化疗组年龄存在显著差异,可能影响结局比较。
  • 总生存期无显著差异,需更长期随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Intraperitoneal (IP) chemotherapy following neoadjuvant chemotherapy (NACT) and interval tumor reductive surgery (TRS) for advanced ovarian cancer is feasible, however, the impact on disease outcomes remains unclear. We compare outcomes of patients treated with IP chemotherapy versus intravenous (IV) chemotherapy following NACT and interval TRS. METHODS: In this retrospective review, patients with advanced ovarian cancer were included if they received NACT followed by optimal interval TRS between 1/2004 and 4/2017. Patients were excluded if they had an ECOG PS >1, received >6 cycles of NACT or postoperative chemotherapy, and/or received bevacizumab during primary therapy. Primary outcomes were progression free survival (PFS) and overall survival (OS). RESULTS: There were 134 patients included in this study, 37 (28%) received IP and 97 (72%) received IV chemotherapy postoperatively. Patients in the IV group were older (median 66.3 vs 59.7 years, p = 0.0039) though there were no differences in BMI, race, BRCA status, stage, or histology. Median PFS was 3 months longer in the IP group (14.5 versus 11.5 months, p = 0.028) however there was no significant difference in OS. On univariate analysis, increasing number of NACT cycles (HR 1.914, 95% CI 1.024-3.497) and residual disease at completion of TRS (HR 1.541, 95% CI 1.042-2.248) were associated with decreased PFS; IP chemotherapy was associated with increased PFS (HR 0.633, 95% CI 0.414-0.944). These associations remained on multivariate analysis. Toxicity was comparable between the groups. CONCLUSIONS: IP after NACT and optimal interval TRS was associated with in improved PFS compared to IV chemotherapy without significant differences in toxicity.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bixel K, Vetter M, Davidson B, et al. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. Gynecol Oncol. 2020. PMID: 31937450. doi:10.1016/j.ygyno.2019.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。